PTC TherapeuticsPTCT
PTCT
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
126% more call options, than puts
Call options by funds: $5.68M | Put options by funds: $2.51M
19% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 26
17% more capital invested
Capital invested by funds: $2.51B [Q2] → $2.95B (+$437M) [Q3]
2% more funds holding
Funds holding: 197 [Q2] → 201 (+4) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 70
3.47% less ownership
Funds ownership: 106.96% [Q2] → 103.49% (-3.47%) [Q3]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$32
35%
downside
Avg. target
$65
31%
upside
High target
$113
129%
upside
9 analyst ratings
6 positive
67%
1 neutral
11%
2 negative
22%
Cantor Fitzgerald Kristen Kluska 39% 1-year accuracy 42 / 108 met price target | 129%upside $113 | Overweight Maintained | 3 Feb 2025 |
Morgan Stanley Jeffrey Hung 47% 1-year accuracy 8 / 17 met price target | 36%upside $67 | Overweight Upgraded | 13 Dec 2024 |
Citigroup David Lebowitz 55% 1-year accuracy 12 / 22 met price target | 35%downside $32 | Sell Maintained | 4 Dec 2024 |
Goldman Sachs Paul Choi 22% 1-year accuracy 2 / 9 met price target | 15%downside $42 | Sell Maintained | 4 Dec 2024 |
UBS Colin Bristow 12% 1-year accuracy 2 / 17 met price target | 44%upside $71 | Buy Maintained | 3 Dec 2024 |
Financial journalist opinion
Based on 3 articles about PTCT published over the past 30 days
Positive
Zacks Investment Research
19 hours ago
PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last?
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
PRNewsWire
3 weeks ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J. , Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to two new employees.
Neutral
PRNewsWire
3 weeks ago
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
– Unaudited 2024 total revenue of approximately $814 million, exceeding guidance – – Four approval applications submitted to FDA in 2024 – – Global launch preparations underway for sepiapterin for PKU, a $1 billion market opportunity; CHMP opinion expected Q2 2025, U.S. approval decision in July 2025 – – License and collaboration agreement with Novartis for PTC518 program closed – – PIVOT-HD data readout for PTC518 expected Q2 2025 – WARREN, N.J. , Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025.
Neutral
PRNewsWire
1 month ago
PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WARREN, N.J. , Dec. 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B.
Neutral
PRNewsWire
1 month ago
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
- If approved, vatiquinone would be the first and only authorized therapy for children with FA - - PTC's fourth approval application submitted to FDA in 2024 - WARREN, N.J. , Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with Friedreich ataxia (FA) to the U.S. Food and Drug Administration (FDA).
Neutral
PRNewsWire
1 month ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J. , Dec. 17, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 13, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,725 shares of its common stock and 5,060 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to eight new employees.
Positive
Zacks Investment Research
2 months ago
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy
Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.
Positive
Investopedia
2 months ago
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Shares of PTC Therapeutics (PTCT) soared 16% Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis (NVS).
Positive
Benzinga
2 months ago
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecules.
Positive
Investors Business Daily
2 months ago
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
Charts implemented using Lightweight Charts™